



Strategic National Stockpile Smallpox Medical Countermeasures Overview

Steven A. Adams, MPH
Deputy Assistant Secretary
Director, Strategic National Stockpile (SNS)
Administration for Strategic Preparedness and Response
Meeting of the NASEM Committee on Smallpox Medical Countermeasures
December 14, 2023

Unclassified

Smallpox: SNS Countermeasures

	Name	Type	Regulatory Status*
Vaccines	ACAM2000®	Second Generation Live, replicating Lyophilized Frozen; Diluent	FDA Licensed
	JYNNEOS® (MVA-BN)	Third Generation Attenuated Live, non-replicating Liquid Frozen	FDA Licensed
	WetVax (APSV)	First Generation Live, replicating Liquid Frozen	IND/EUA
Therapeutics	Vaccinia Immune Globulin Intravenous (VIGIV)	Intravenous formulation; vaccinia virus antibodies	FDA Licensed
	Tecovirimat (TPOXX®)	Oral capsule and IV formulation (pediatric oral powder for reconstitution under development)	FDA Approved
	Brincidofovir (Tembexa®)	Oral tablet and suspension formulation	FDA Approved

*other regulatory mechanisms may apply based on certain ages, unlabeled indications/routes of administration, other orthopoxviruses

Smallpox: Response Levels

The SNS will be prepared to respond to the following response levels as defined by the **National Vaccine Response Strategy for a Smallpox Emergency**:


- Level 1: Increased preparedness response, which is designed to reduce the risk to healthcare workers, critical infrastructure personnel and first responders
- Level 2: Local response in the form of a local vaccination campaign
- Level 3: National response for a national vaccination campaign

Smallpox: Distribution Snapshot

Vaccine Distribution



SNS Warehouse(s)



State RSS



State RSS



State RSS



State RSS



State RSS



State RSS



State RSS




State RSS



State RSS

Therapeutic Distribution



SNS Warehouse(s)



Local Hospital

Smallpox: Top 5 Things to Know About SNS Response



Flexible

Vaccination strategy determined at time of incident collectively by federal public health officials and State, Local, Tribal, Territorial (SLTT) partners



Fast

SNS delivery can be **fast**. Shipping will begin within 8 hours after direction to deploy. SNS vaccine delivery via **push** to jurisdiction's identified "ship to" locations



Comprehensive Stockpile

SNS maintains sufficient inventory to vaccinate the entire U.S. population

- **Multiple types of vaccines**
- **Pre-built kits for ACAM2000 and WetVax**— each kit contains enough vaccine and ancillaries for 10,000 people
- Additional vaccine for immunocompromised individuals



Cold Chain Management for Vaccines

- Jurisdictions need to be prepared to maintain cold chain protocols
- Jurisdictions may need to repackage/further distribute to support local vaccination campaign strategies



Treatment & Adverse Events

SNS maintains vaccinia immune globulin (VIG), tecovirimat (TPOXX), and brincidofovir (Tembexa) for treatment and/or vaccine adverse events. Delivered upon request (**pull process**). Shipped separately to points of care.

Mpox Response Lessons Learned

- Mpox response was not the same as smallpox would be
 - Smallpox response plan has always assumed a full mobilization/"push" to pre-identified "ship to" locations
 - Mpox outbreak presented as a public health threat that primarily affected a specific demographic and required targeted, nationwide outreach and access
- What did SNS learn and what was confirmed?
 - As a response evolves and expands, distribution strategy may need to adjust
 - Commercial distributors can assist when response requires direct shipment to many providers nationwide
 - Large community events and federally qualified health centers can reach targeted populations and improve access
 - Immunization managers play key role in a public health response that requires vaccine
 - Cold-chain management is crucial to ensure public health and health care facilities and providers can maintain product delivered from the SNS

Questions and Comments



Contact Us

Steven A. Adams, MPH
Deputy Assistant Secretary
Director, Strategic National Stockpile
saa1@cdc.gov

<https://www.phe.gov/about/sns/Pages/default.aspx>